Unknown

Dataset Information

0

Hepatic dysfunction and thrombocytopenia induced by excess sFlt1 in mice lacking endothelial nitric oxide synthase.


ABSTRACT: Liver dysfunction is a major problem in patients with severe preeclampsia (PE), hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome, or in patients receiving anti-vascular endothelial growth factor (VEGF) therapy. Excessive soluble fms-like tyrosine kinase 1 (sFlt1) that antagonizes VEGF has been implicated in the pathogenesis of PE. VEGF increases the expression of endothelial nitric oxide synthase (eNOS) and activates it. eNOS polymorphisms that cause reduced NO production are associated with PE. The aim of this study was to clarify the role on hepatic function by excess sFlt1 in the absence of eNOS gene product. We first overexpressed sFlt1 using adenovirus in eNOS -/- and eNOS +/+ mice. Excessive sFlt1 and lack of eNOS synergistically increased plasma levels of liver transaminases, exacerbated infiltration of inflammatory cells, elevated expression levels of cytokines in the liver, and aggravated oxidative stress and coagulation abnormalities. Lack of eNOS in the presence of excess sFlt1 also induced thrombocytopenia, whereas eNOS +/+ mice with excess sFlt1 alone showed no or modest liver phenotype. Taken together, excessive sFlt1 and lack of eNOS synergistically induce hepatic dysfunction and thrombocytopenia, suggesting a novel role for VEGF and nitric oxide signaling in hepatocyte-endothelial cross-talk in health and in liver injury states.

SUBMITTER: Oe Y 

PROVIDER: S-EPMC5758763 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Hepatic dysfunction and thrombocytopenia induced by excess sFlt1 in mice lacking endothelial nitric oxide synthase.

Oe Yuji Y   Ko Mieko M   Fushima Tomofumi T   Sato Emiko E   Karumanchi S Ananth SA   Sato Hiroshi H   Sugawara Junichi J   Ito Sadayoshi S   Takahashi Nobuyuki N  

Scientific reports 20180108 1


Liver dysfunction is a major problem in patients with severe preeclampsia (PE), hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome, or in patients receiving anti-vascular endothelial growth factor (VEGF) therapy. Excessive soluble fms-like tyrosine kinase 1 (sFlt1) that antagonizes VEGF has been implicated in the pathogenesis of PE. VEGF increases the expression of endothelial nitric oxide synthase (eNOS) and activates it. eNOS polymorphisms that cause reduced NO producti  ...[more]

Similar Datasets

| S-EPMC1571697 | biostudies-literature
| S-EPMC4297730 | biostudies-literature
| S-EPMC7285905 | biostudies-literature
| S-EPMC7531049 | biostudies-literature
| S-EPMC3939925 | biostudies-literature
| S-EPMC2874202 | biostudies-literature
| S-EPMC4628887 | biostudies-literature
| S-EPMC6337296 | biostudies-literature
| S-EPMC2819317 | biostudies-literature
| S-EPMC1987713 | biostudies-literature